ET0111
/ Etern Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 31, 2022
FLIGHT: FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=37 | Recruiting | Sponsor: Etern BioPharma (Shanghai) Co., Ltd
Monotherapy • New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1